Stocks · News reference
Filed: 2026-08-12 AccNo: 0001193125-26-345753 Size: 368 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Xilio Therapeutics granted non-qualified stock options to purchase 19,865 shares to two new employees at an exercise price of $8.88 per share on September 1, 2026. The options have a ten-year term with 25% vesting on the first anniversary and the remaining 75% vesting monthly over three years, subject to continued employment.
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.59) by 44.07 percent. This is a 85.27 percent increase over losses of $(2.24) per share